Dopamine agonist therapy and cardiac valve dysfunction

Clinical Endocrinology

Volumn 67, Issue 5, 2007, Pages 643-644

  Sherlock, Mark ^a   Steeds, Richard ^b   Toogood, Andy A ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; QUINAGOLIDE; ROPINIROLE; SELEGILINE;

DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART VALVE DYSFUNCTION; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; MITRAL VALVE REGURGITATION; NOTE; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

DOPAMINE AGONISTS; FIBROBLASTS; FIBROSIS; HEART VALVES; HUMANS; HYPERPROLACTINEMIA; PARKINSON DISEASE; RECEPTORS, SEROTONIN;

EID: 35448973304     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02974.x     Document Type: Note

References (9)

1. Gillam, M.P., Molitch, M.E., Lombardi, G. Colao, A. (2006) Advances in the treatment of prolactinomas. Endocrine Reviews, 27, 485 534.
2. Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C. Schoors, D. (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet, 363, 1179 1183.
3. Roth, B.L. (2007) Drugs and valvular heart disease. New England Journal of Medicine, 356, 6 9.
4. Rothman, R.B., Baumann, M.H., Savage, J.E., Rauser, L., McBride, A., Hufeisen, S.J. Roth, B.L 2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 102, 2836 2841.
5. Setola, V., Hufeisen, S.J., Grande-Allen, K.J., Vesely, I., Glennon, R.A., Blough, B., Rothman, R.B. Roth, B.L 2003) 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Molecular Pharmacology, 63, 1223 1229.
6. Kvernmo, T., Hartter, S. Burger, E. (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical Therapeutics, 28, 1065 1078.
7. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. Garbe, E. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29 38.
8. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S. Pezzoli, G. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine, 356, 39 46.
9. Linkova, H., Ruzicka, E. Penicka, M. (2007) Dopamine agonists and valvular heart disease. New England Journal of Medicine, 356, 1676 author reply 1678 1680.